至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4

PLoS Pathog. 2022-06; 
Hugh C Welles, Hannah A D King, Leonard Nettey, Nicole Cavett, Jason Gorman, Tongqing Zhou, Yaroslav Tsybovsky, Renguang Du, Kaimei Song, Richard Nguyen, David Ambrozak, Amy Ransier, Chaim A Schramm, Nicole A Doria-Rose, Adrienne E Swanstrom, James A Hoxie, Celia LaBranche, David C Montefiori, Daniel C Douek, Peter D Kwong, John R Mascola, Mario Roederer, Rosemarie D Mason
Products/Services Used Details Operation
DNA Sequencing … Sequenced antibody variable regions were synthesized (GenScript) and cloned into murine heavy and light chain antibody expression vectors. Antibodies were expressed in Expi293F … Get A Quote

摘要

Both SIV and SHIV are powerful tools for evaluating antibody-mediated prevention and treatment of HIV-1. However, owing to a lack of rhesus-derived SIV broadly neutralizing antibodies (bnAbs), testing of bnAbs for HIV-1 prevention or treatment has thus far been performed exclusively in the SHIV NHP model using bnAbs from HIV-1-infected individuals. Here we describe the isolation and characterization of multiple rhesus-derived SIV bnAbs capable of neutralizing most isolates of SIV. Eight antibodies belonging to two clonal families, ITS102 and ITS103, which target unique epitopes in the CD4 binding site (CD4bs) region, were found to be broadly neutralizing and together neutralized all SIV strains tested. A rare f... More

关键词